281 related articles for article (PubMed ID: 15930318)
1. Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses.
Liu Y; Bi X; Xu S; Xiang J
Cancer Res; 2005 Jun; 65(11):4955-62. PubMed ID: 15930318
[TBL] [Abstract][Full Text] [Related]
2. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
[TBL] [Abstract][Full Text] [Related]
4. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M
Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590
[TBL] [Abstract][Full Text] [Related]
5. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses.
Yang AS; Lattime EC
Cancer Res; 2003 May; 63(9):2150-7. PubMed ID: 12727833
[TBL] [Abstract][Full Text] [Related]
6. CD4+ Th2 cells function alike effector Tr1 and Th1 cells through the deletion of a single cytokine IL-6 and IL-10 gene.
Ankathatti Munegowda M; Xu S; Freywald A; Xiang J
Mol Immunol; 2012 Jun; 51(2):143-9. PubMed ID: 22424785
[TBL] [Abstract][Full Text] [Related]
7. CD40 ligation converts TGF-beta-secreting tolerogenic CD4-8- dendritic cells into IL-12-secreting immunogenic ones.
Zhang X; Kedl RM; Xiang J
Biochem Biophys Res Commun; 2009 Feb; 379(4):954-8. PubMed ID: 19135981
[TBL] [Abstract][Full Text] [Related]
8. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
[TBL] [Abstract][Full Text] [Related]
9. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
[TBL] [Abstract][Full Text] [Related]
10. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
Chen PW; Ksander BR
Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
[TBL] [Abstract][Full Text] [Related]
11. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].
Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158
[TBL] [Abstract][Full Text] [Related]
12. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
Li T; Harada M; Tamada K; Abe K; Nomoto K
Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
Gabrilovich DI; Ciernik IF; Carbone DP
Cell Immunol; 1996 May; 170(1):101-10. PubMed ID: 8665590
[TBL] [Abstract][Full Text] [Related]
14. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
15. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
16. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells generated in the presence of interferon-alpha stimulate allogeneic CD4+ T-cell proliferation: modulation by autocrine IL-10, enhanced T-cell apoptosis and T regulatory type 1 cells.
Carbonneil C; Saidi H; Donkova-Petrini V; Weiss L
Int Immunol; 2004 Jul; 16(7):1037-52. PubMed ID: 15184347
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.
Saha A; Chatterjee SK; Foon KA; Primus FJ; Sreedharan S; Mohanty K; Bhattacharya-Chatterjee M
Cancer Res; 2004 Jul; 64(14):4995-5003. PubMed ID: 15256474
[TBL] [Abstract][Full Text] [Related]
19. Characterization of tumor-infiltrating CD4+ T cells as Th1 cells based on lymphokine secretion and functional properties.
Nagarkatti M; Clary SR; Nagarkatti PS
J Immunol; 1990 Jun; 144(12):4898-905. PubMed ID: 1972170
[TBL] [Abstract][Full Text] [Related]
20. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]